Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02220023 · ClinicalTrials.gov registry record · Early Phase 1
Dynamic Assessment of Right Ventricular Function With Inhaled Nitric Oxide During Cardiac MRI
A Early Phase 1 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
NCT02220023 is a Early Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 17 participants.
The verdict
NCT02220023, a Early Phase 1 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of the study is to measure RV ejection fraction (RVEF), pulmonary flow, and pulmonary perfusion before and after exposure to inhaled nitric oxide in patients with pulmonary arterial hypertension (PAH) who are known to be vasodilator-responsive based on invasive catheterization as well as healthy subjects. Measurements will also be made after high flow oxygen alone to test the relative vasodilatory effect of oxygen and NO. The investigators hypothesize is that inhaled nitric oxide during cardiac MRI can be used to measure dynamic changes in RV-pulmonary vascular function in patients with vasodilator-responsive PAH.
Interventions
- DRUG INOmax Inhalation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2014-07 |
| Est. Completion | 2017-02 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02220023
The ClinicalTrials.gov registry entry for NCT02220023 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INOmax Inhalation is the first listed.
NCT02220023 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02220023 about?
NCT02220023 is a clinical study titled "Dynamic Assessment of Right Ventricular Function With Inhaled Nitric Oxide During Cardiac MRI". The purpose of the study is to measure RV ejection fraction (RVEF), pulmonary flow, and pulmonary perfusion before and after exposure to inhaled nitric oxide in patients with pulmonary arterial hypertension (PAH) who are known to be vasodilator-responsive based on invasive catheterization as well as...
What is the current status of trial NCT02220023?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2014-07. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02220023?
The interventions under investigation include: INOmax Inhalation (DRUG).
Who is sponsoring clinical trial NCT02220023?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.